Full Name
Dr. Alex F. Herrera MD
Job Title
Assistant Professor, Division of Lymphoma
Company/Affiliation
City of Hope
Speaker Bio
Alex Herrera, M.D., earned his undergraduate degree summa cum laude from Princeton University and received his medical degree from Harvard Medical School. Dr. Herrera completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital.
Dr. Herrera's clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. He is the principal investigator of over 40 clinical trials evaluating novel agents for the treatment of Hodgkin or non-Hodgkin lymphomas, including 17 investigator-initiated trials. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation with the goal of designing biomarker-based clinical trials to improve outcomes and personalize lymphoma treatment.
Dr. Herrera is the recipient of several honors, grants and awards, including the Toni and Emmet Stephenson Leukemia & Lymphoma Society Scholar in Clinical Research Award, V Foundation Clinical Scholar Program Award, American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator, American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award, City of Hope K12 Paul Calabresi Career Development Award for Clinical Oncology, and the Lymphoma Research Foundation Larry and Denise Mason Clinical Investigator Career Development Award. He has published over 130 peer-reviewed publications and book chapters, and has been invited to present his work nationally and internationally. Dr. Herrera is a member of several national and international guidelines committees including the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma, the Southwest Oncology Group Lymphoma Committee Working Group, the Center for International Blood and Marrow Transplant Research (CIBMTR) Committee on Practice Guidelines, and he is a co-chair of the CIBMTR Lymphoma Working Committee.
Dr. Herrera's clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. He is the principal investigator of over 40 clinical trials evaluating novel agents for the treatment of Hodgkin or non-Hodgkin lymphomas, including 17 investigator-initiated trials. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation with the goal of designing biomarker-based clinical trials to improve outcomes and personalize lymphoma treatment.
Dr. Herrera is the recipient of several honors, grants and awards, including the Toni and Emmet Stephenson Leukemia & Lymphoma Society Scholar in Clinical Research Award, V Foundation Clinical Scholar Program Award, American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator, American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award, City of Hope K12 Paul Calabresi Career Development Award for Clinical Oncology, and the Lymphoma Research Foundation Larry and Denise Mason Clinical Investigator Career Development Award. He has published over 130 peer-reviewed publications and book chapters, and has been invited to present his work nationally and internationally. Dr. Herrera is a member of several national and international guidelines committees including the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma, the Southwest Oncology Group Lymphoma Committee Working Group, the Center for International Blood and Marrow Transplant Research (CIBMTR) Committee on Practice Guidelines, and he is a co-chair of the CIBMTR Lymphoma Working Committee.
Speaking At
